Note 15 - Segments - Operations by Segment (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Revenue from Contract with Customer, Excluding Assessed Tax	$ 149,952	$ 173,686
Cost of Goods and Services Sold	107,332	131,617
Gross Profit	42,620	42,069
Selling, General and Administrative Expense	59,086	70,167
Research and Development Expense	30,841	21,937
Amortization of Intangible Assets	19,861	21,437
Operating loss	(67,168)	(71,472)
Depreciation and amortization	23,487	25,820
UNITED STATES
Revenue from Contract with Customer, Excluding Assessed Tax	116,207	136,043
IRELAND
Revenue from Contract with Customer, Excluding Assessed Tax	5,480	9,222
CHILE
Revenue from Contract with Customer, Excluding Assessed Tax	14,532	14,889
SPAIN
Revenue from Contract with Customer, Excluding Assessed Tax	6,439	5,659
ISRAEL
Revenue from Contract with Customer, Excluding Assessed Tax	73	160
MEXICO
Revenue from Contract with Customer, Excluding Assessed Tax	6,229	7,083
Other Countries [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	992	630
Service [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	102,844	126,890
Cost of Goods and Services Sold	84,518	109,873
Product [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	34,842	38,047
Cost of Goods and Services Sold	22,814	21,744
Transfer of Intellectual Property and Other [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	12,266	8,749
Operating Segments [Member] | Pharmaceutical [Member]
Cost of Goods and Services Sold	22,814	21,743
Gross Profit	24,294	25,053
Selling, General and Administrative Expense	12,710	15,040
Research and Development Expense	30,238	21,247
Amortization of Intangible Assets	16,111	16,443
Operating loss	(34,765)	(27,677)
Depreciation and amortization	17,788	17,952
Operating Segments [Member] | Pharmaceutical [Member] | Service [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	0	0
Operating Segments [Member] | Pharmaceutical [Member] | Product [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	34,842	38,047
Operating Segments [Member] | Pharmaceutical [Member] | Transfer of Intellectual Property and Other [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	12,266	8,749
Operating Segments [Member] | Diagnostics [Member]
Cost of Goods and Services Sold	84,518	109,874
Gross Profit	18,326	17,016
Selling, General and Administrative Expense	37,956	45,761
Research and Development Expense	538	665
Amortization of Intangible Assets	3,750	4,994
Operating loss	(23,918)	(34,404)
Depreciation and amortization	5,699	7,868
Operating Segments [Member] | Diagnostics [Member] | Service [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	102,844	126,890
Operating Segments [Member] | Diagnostics [Member] | Product [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	0	0
Operating Segments [Member] | Diagnostics [Member] | Transfer of Intellectual Property and Other [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	0	0
Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]
Cost of Goods and Services Sold	0	0
Gross Profit	0	0
Selling, General and Administrative Expense	8,420	9,366
Research and Development Expense	65	25
Amortization of Intangible Assets	0	0
Operating loss	(8,485)	(9,391)
Depreciation and amortization	0	0
Segment Reporting, Reconciling Item, Corporate Nonsegment [Member] | Service [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	0	0
Segment Reporting, Reconciling Item, Corporate Nonsegment [Member] | Product [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	0	0
Segment Reporting, Reconciling Item, Corporate Nonsegment [Member] | Transfer of Intellectual Property and Other [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	$ 0	$ 0